Sign In
Buy ONCY
$0.94
+0.0237 (+2.58%)
At Close: Jun 23, 2026
Trial-in-progress abstract highlights new cohort that could expand the company's pancreatic cancer program Pelareorep's ability to expand TILs highlights its immunotherapeutic mechanism of action and
Oncolytics Biotech® Announces Voting Results from the Annual General Meeting of Shareholders
07:00am, Thursday, 16'th May 2024
SAN DIEGO and CALGARY, AB , May 16, 2024 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today annou
Oncolytics Biotech® Announces Preliminary Collaboration with GCAR for Inclusion of Pelareorep in Anticipated Pancreatic Cancer Trial
07:00am, Wednesday, 15'th May 2024
Anticipated evaluation to include combination therapy featuring treatment regimen of checkpoint inhibition and chemotherapy utilized in cohort 1 of the GOBLET study GCAR is launching a new master prot
Oncolytics Biotech, Inc. (ONCY) Q1 2024 Earnings Call Transcript
08:48pm, Thursday, 09'th May 2024
Oncolytics Biotech, Inc. (NASDAQ:ONCY ) Q1 2024 Earnings Conference Call May 9, 2024 4:30 PM ET Company Participants Jon Patton - Director, Investor Relations and Communication Matthew Coffey - Presid
Oncolytics Biotech® Reports First Quarter 2024 Financial Results and Operational Highlights
04:01pm, Thursday, 09'th May 2024
Pelareorep advancing to registration-enabling studies Preparations underway for Type C meeting with the FDA to establish registrational pathway in HR+/HER2- metastatic breast cancer Overall survival d
US$5 million PanCAN grant provides important support for the fifth cohort of the GOBLET study Study of modified FOLFIRINOX/pelareorep/atezolizumab (Tecentriq®) combination expands existing pancreatic
Oncolytics Biotech® to Participate in a Fireside Chat at the 2024 RBC Capital Markets Global Healthcare Conference
07:00am, Wednesday, 08'th May 2024
SAN DIEGO and CALGARY, AB , May 8, 2024 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today announc
Oncolytics Biotech® to Host Conference Call to Discuss First Quarter Financial Results and Recent Operational Highlights
07:00am, Tuesday, 30'th Apr 2024
Conference call and webcast to take place on Thursday, May 9, 2024, at 4:30 p.m. ET SAN DIEGO and CALGARY, AB , April 30, 2024 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a
Oncolytics Biotech® Announces Upcoming Presentations at the American Society of Clinical Oncology Annual Meeting
07:00am, Thursday, 25'th Apr 2024
SAN DIEGO and CALGARY, AB , April 25, 2024 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today anno
Requested for Q2 2024, the Type C meeting is to focus on planned registration-enabling trial in HR+/HER2- metastatic breast cancer Overall survival results from the randomized HR+/HER2- metastatic bre
Oncolytics Biotech® to Participate in a Panel Presentation at Canaccord Genuity's Horizons in Oncology Virtual Conference
07:00am, Tuesday, 02'nd Apr 2024
SAN DIEGO and CALGARY, AB , April 2, 2024 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a clinical-stage immunotherapeutics company focused on oncology, today announced that Pr
Oncolytics Biotech, Inc. (ONCY) Q4 2023 Earnings Call Transcript
01:09am, Saturday, 09'th Mar 2024
Oncolytics Biotech, Inc. (ONCY) Q4 2023 Earnings Call Transcript
Oncolytics Biotech® Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights
04:01pm, Thursday, 07'th Mar 2024
Pelareorep advancing to a registration-enabling study in 2024 in pancreatic cancer and expands pancreatic potential with new GOBLET cohort in combination with mFOLFIRINOX Impressive objective response
Oncolytics Biotech® Files Amendment to Initiate New Pancreatic Cancer GOBLET Cohort Supported by PanCAN
07:00am, Tuesday, 05'th Mar 2024
US$5M grant supports study of pelareorep in combination with modified FOLFIRINOX +/- atezolizumab Testing with the most common therapies could facilitate broad use of pelareorep in pancreatic cancer
Conference call and webcast to take place on Thursday, March 7, 2024, at 4:30 p.m. ET SAN DIEGO and CALGARY, AB , March 4, 2024 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a
